Alzamend Neuro is trading 17.77% higher at $1.57 in after-hours, with no clear company-specific catalyst identified.
- It closed the October 1 regular session at $1.33, after falling 23.12%.
- Its investor-relations press-release page lists September 16, 2026, as its latest announcement, about regaining Nasdaq listing compliance; that earlier news does not establish a reason for this move.
- Major indices were little changed, so broad-market direction does not clearly explain the move.